12th International Congress on Targeted Anticancer Therapies

lung cancer
lymphoma

Belinostat Moves Forward in Trials for Two Aggressive Cancers

In February, the U.S. Food and Drug Administration (FDA) granted belinostat (Beleodaq), a targeted histone deacetylase (HDAC) inhibitor, priority review status based on a pivotal phase II trial in per...

Advertisement

Advertisement



Advertisement